Public health governance in rapidly expanding industrial economies faces a persistent challenge: regulatory enforcement often remains reactive, responding to individual violations only after they have produced visible harm. In emerging markets, regulatory authorities must oversee complex supply chains involving food manufacturers, pharmaceutical companies, retailers, restaurants and other commercial actors. This makes conventional inspection-based regulation difficult to sustain. However, when regulatory institutions combine systematic surveillance, laboratory testing, market inspections and decisive legal intervention, they can move beyond isolated enforcement toward a more preventive model of public health governance.
Recent enforcement actions by the Maharashtra Food and Drug Administration (FDA) provide a useful case study of this transition. Across food safety, dairy regulation, pharmaceutical quality and school nutrition, the state has adopted interventions that illustrate how regulatory agencies can respond to both immediate safety threats and longer-term public-health risks.
Tackling Food Fraud Through Systematic Surveillance
The scale of the problem became particularly evident in Maharashtra’s dairy sector. Between April 1, 2025 and March 31, 2026, the Maharashtra FDA collected and analysed 308 samples of paneer and dairy products through notified food laboratories. Of these, 109 samples, approximately 35.4 per cent, failed to conform to prescribed standards. Seventy-nine were classified as sub-standard, while 30 were declared unsafe. Laboratory analysis also identified abnormal butyro-refractometer readings and iodine values in a significant proportion of samples, indicating the addition or substitution of vegetable or other non-milk fats.
These findings contributed to a major regulatory intervention. On July 30, 2026, Maharashtra Food Safety Commissioner Tukaram Mundhe issued an order prohibiting the manufacture, processing, preparation, packing, storage, transportation, distribution and sale of analogue or non-dairy paneer across Maharashtra for one year. The order was issued under Section 30(2)(a), read with Sections 18 and 29, of the Food Safety and Standards Act, 2006.
The regulatory concern was not simply that analogue products contained non-dairy ingredients. A central issue was that such products were reportedly being used or sold in ways that could lead consumers to believe they were purchasing conventional dairy paneer. The FDA specifically addressed the use of analogue paneer by hotels, restaurants, caterers and cloud kitchens. Representing a product as genuine paneer when its composition does not correspond to the prescribed standard can raise issues of misleading representation and unfair trade practices under Section 24 of the FSS Act.
This distinction is important for public-health policy. The principal regulatory concern is not merely the presence of vegetable fat; it is the combination of non-standardised products, inadequate disclosure, traceability problems and potential consumer deception. The intervention therefore represents an attempt to address both supply-side non-compliance and information asymmetry between producers and consumers.
Hygiene Standards and the Parsi Dairy Farm Case
Regulatory enforcement simultaneously extended beyond adulteration and product composition to the basic hygiene of food-production facilities. One prominent example was the suspension of the food licence of Mumbai’s historic Parsi Dairy Farm.
Following an inspection in July 2026, Maharashtra FDA officials reported fungal growth on walls in storage and production areas, raw materials stored directly on the floor, inadequate pest-control measures, the absence of a protected raw-milk reception dock and other food-safety deficiencies. The inspection also identified problems involving sanitation, food-handler records and product labelling. The establishment’s licence was subsequently suspended with immediate effect.
The case illustrates an important principle of public-health regulation: institutional reputation cannot substitute for compliance. A business with a long commercial history remains subject to the same hygiene, sanitation, licensing and food-safety requirements as newer establishments. The regulatory objective is therefore not to target a particular brand but to ensure that established reputation does not become an alternative to documented compliance.
Pharmaceutical Regulation and the Threat of Toxic Contamination
Food safety, however, is only one dimension of public-health protection. Pharmaceutical regulation carries an even more immediate significance because contamination of medicines can directly threaten human life.
In 2025, concerns over diethylene glycol (DEG) and ethylene glycol contamination in paediatric cough medicines emerged in India. Products identified in connection with the contamination included Coldrif, ReLife Syrup manufactured by Shape Pharma Pvt. Ltd., and Respifresh-TR manufactured by Rednex Pharmaceuticals Pvt. Ltd. The United States Food and Drug Administration, citing information from Indian health authorities, confirmed that these products had been recalled in India.
Maharashtra also issued prohibition action against Re-Life and Respifresh-TR after testing identified DEG contamination above permitted limits. The state action required the affected products to be withdrawn from sale and use.
The significance of DEG contamination lies in its severe toxicological consequences. Exposure can result in serious kidney injury, neurological damage and, in severe cases, death. The international history of contaminated paediatric medicines demonstrates why raw-material verification, supplier qualification, laboratory testing and finished-product quality control are essential components of pharmaceutical regulation. The 2025 cases therefore underline a broader regulatory lesson: preventing pharmaceutical disasters requires surveillance at multiple points in the supply chain rather than relying solely on postmarket complaints.
Moving From Food Safety to Preventive Health Policy
Maharashtra’s regulatory approach has also expanded into the food environments surrounding children. In July 2026, the state introduced restrictions on high-fat, high-sugar and high-salt (HFSS) foods within schools and within a 50-metre radius of school premises. The restrictions cover the sale, distribution and advertising of such products, while school canteens and related food operations have also been subjected to food-safety licensing requirements.
This represents a shift from conventional food regulation toward preventive public health. Instead of intervening only when food becomes contaminated or adulterated, the policy attempts to influence the environment in which children make dietary choices. Limiting the availability and promotion of HFSS products around educational institutions can therefore be understood as an environmental approach to nutrition policy.
Such interventions are particularly relevant in the context of rising concerns about childhood obesity, unhealthy dietary patterns and metabolic disease. Regulation of the school food environment does not eliminate these problems, but it demonstrates how public-health agencies can use regulatory authority to reduce exposure to unhealthy commercial food environments among vulnerable populations.
From Fragmented Inspections to Systemic Regulation
Taken together, these interventions illustrate a broader transformation in regulatory thinking. The Maharashtra FDA’s recent activities show how laboratory surveillance, market inspections, licensing actions, product prohibitions and preventive food policies can operate as interconnected components of public-health governance.
The analogue-paneer investigation demonstrates the value of systematic sampling and laboratory analysis. The Parsi Dairy Farm case illustrates the importance of enforcing hygiene and licensing standards irrespective of institutional reputation. The contaminated cough-syrup episode demonstrates the necessity of rigorous pharmaceutical quality control and rapid product withdrawal. Meanwhile, the HFSS restrictions around schools show how regulation can be used not merely to prevent contamination but also to shape healthier environments.
The legal framework reinforces this approach. Under Section 59 of the Food Safety and Standards Act, 2006, punishment for unsafe food varies according to the consequences of the offence. Where unsafe food results in death, the law provides for imprisonment of not less than seven years, potentially extending to life imprisonment, along with a substantial fine.
Importantly, such severe penalties apply to the specific circumstances established under the statute; they should not be interpreted as a blanket punishment for every food-safety violation. This distinction is essential for accurate legal and policy analysis.
The Maharashtra case demonstrates that effective public-health governance depends on more than occasional inspections or crisis-driven action. It requires sustained surveillance, laboratory capacity, traceability, transparent standards and the administrative willingness to intervene when violations are identified.
The state’s actions against non-dairy paneer, its suspension of a prominent dairy establishment over hygiene deficiencies, its response to contaminated pharmaceutical products and its restrictions on HFSS foods around schools represent different forms of the same regulatory philosophy: public health must be protected across the entire supply and consumption chain.
The broader lesson for developing and industrialising economies is therefore clear. Regulatory effectiveness is strongest when enforcement moves from isolated reaction toward systematic prevention. Data-backed surveillance can identify patterns of non-compliance; laboratory testing can provide objective evidence; licensing mechanisms can compel institutional compliance; and targeted restrictions can address emerging health risks before they become larger public-health crises.
Ultimately, public safety cannot depend solely on public outrage after harm has occurred. It requires institutions capable of detecting risks early, enforcing standards consistently and adapting regulation to the changing realities of food, medicine and consumer markets. Maharashtra’s recent regulatory interventions provide a valuable example of how state-level public-health governance can evolve from reactive inspection toward a more integrated and preventive model of regulation.
References
- The Indian Express report. The Indian Express — Parsi Dairy Farm licence suspension.
- U.S. FDA — Contaminated Indian cough medicines and DEG/EG concerns. https://www.fda.gov
- Maharashtra FDA action concerning Respifresh-TR and Re-Life Syrup. https://www.corpseed.com
- Maharashtra school HFSS restrictions / 50-metre rule. https://uat.mahafda.in